IntegraGen, Inc. Announces the Publication of the Results of an International Study With its 5-Gene Prognostic Molecular Signature for Hepatocellular Carcinoma Patients in Gastroenterology
7/8/2013 10:56:32 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
EVRY, France--(BUSINESS WIRE)--IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, announced today the publication of a study in the online edition of Gastroenterology reporting results with its proprietary 5-gene expression molecular signature. The study authors report that the molecular signature demonstrates the ability to accurately predict the clinical prognosis of patients with a primary liver cancer (hepatocellular carcinoma) and in whom surgical resection of the affected part of the liver is being considered. The signature allows for the determination of which patients will likely benefit the most from the surgery. The paper, entitled A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection can be found in its entirety online at www.gastrojournal.org.
Help employers find you! Check out all the jobs and post your resume.